がん診断の世界市場規模：診断タイプ別、がんタイプ別、地域別、範囲および予測

がん診断の市場規模と予測

がん診断市場規模は、2024年に1,117億米ドルと評価され、2031年には1,884億3,000万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは6.77%で成長すると予測されます。世界のがん診断市場は、バイオマーカー、イメージングなど様々な分野における技術進歩の増加、がん患者数の増加、高齢者人口の急増、政府による啓発活動、政府資金の増加などにより、力強い成長を遂げています。当レポートは、世界のがん診断市場を総合的に評価したものです。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

世界のがん診断市場の定義

がんは、世界で最もポピュラーな総合疾患の1つです。がんを発見するプロセスには、その診断に特化した特定の技術や装置の使用が含まれます。がんによる死亡は、適切かつ事前の診断によって予防・管理することができます。がんの診断とは、がんの徴候が現れた患者ががんであることを確認することです。早期診断は効果的な治療につながり、患者の生存の可能性を確保します。効果的な診断検査は、病気の存在を確認または除外し、病気の経過を観察し、治療計画を立て、治療効果を決定するために行われます。

病状が改善した場合、採取した検体の質が良くなかった場合、異常な検査結果を確認する必要がある場合など、再検査が重要な場合もあります。がんの診断方法には、画像検査、臨床検査（腫瘍マーカーの検査を含む）、腫瘍生検、内視鏡検査、手術、遺伝子検査などがあります。がんの診断は健康診断から始まります。それによって、がん障害に共通する特定のバイオマーカーやタンパク質が検出され、診断が行われます。がんを検出するもう1つの顕著なプロセスには、特にその診断に使用される特定の技術や機器の使用が含まれます。

がん診断の世界市場概要

世界のがん診断市場は、革新的な製品の継続的なイントロダクションと、様々な疾患の早期診断に対するニーズの高まりが主な要因となっています。また、ヘルスケアと診断分野の急成長は、信頼性の高い結果を出すために腫瘍スクリーニングを更新した技術的に高度な検査システムの参入に起因しています。がんの罹患率の増加は、これらのスクリーニング検査や疾患の進行を観察するために使用される画像診断の市場を活性化し、市場の成長を牽引しています。

世界保健機関（WHO）によると、がんは世界的に死亡原因の第2位であり、2018年には約960万人が死亡しました。米国国立がん研究所（NCI）は、2030年までに年間の新規がん患者数が2,360万人に達すると決定しています。さらに、がん診断の研究開発も市場の成長を助けると予想されています。例えば、2020年1月、ポルトガルのポルト大学の研究者らは、糖鎖工学を用いた胃がんモデルを用いて、モノクローナル抗体によるCD44v9（ヒト消化管がん細胞で発現する主要なタンパク質スプライスバリアント）の検出におけるO-グリコシル化の役割の評価を報告しました。

しかし、不十分な償還政策が市場の成長を阻害すると予想されます。近年、画像診断装置に関する放射線医学の進歩は多岐にわたる。ほとんどの医療保険会社では、コンピュータ支援検出（CAD）を利用した手技に対する償還を提供していないです。さらに、がん検出ソフトウェアの高価格も市場成長の妨げになると予想されています。コンピュータ支援検出（CAD）ソフトウェアは1年間のライセンスで入手でき、病院は毎年更新する必要があります。それにもかかわらず、准動物のがんのための生検プラットフォームの開発は、世界のがん診断市場のプレーヤーに有益な成長機会を提供すると期待されています。さらに、がんの迅速な発見におけるAIの使用もまた、市場の成長を助けると考えられています。

目次

第1章 世界のがん診断市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のがん診断市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 がん診断の世界市場：診断タイプ別

• 概要
• 生検および細胞診検査
• 画像診断検査
• 内視鏡検査
• 遺伝子検査
• その他

第6章 がん診断の世界市場：がんタイプ別

• 概要
• 乳がん
• 白血病
• 膵臓がん
• 前立腺がん
• 結腸および直腸がん
• その他

第7章 がん診断の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界のがん診断市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• Illumina, Inc.
• Koninklijke Philips N.V.
• Agilent Technologies, Inc.
• General Electric Company
• F. Hoffmann-La Roche Ltd.
• Becton, Dickinson and Company

第10章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第11章 付録

• 関連調査

Cancer Diagnostics Market Size And Forecast

Cancer Diagnostics Market size was valued at USD 111.70 Billion in 2024 and is projected to reach USD 188.43 Billion by 2031 , growing at a CAGR of 6.77% during the forecast period 2024-2031. The global Cancer Diagnostics Market has witnessed strong growth owing to the increasing technological advancements in various fields such as biomarkers, imaging, etc., a growing number of cancer cases, rapid growth in the geriatric population, awareness actions by governments, and growing government funding. The Global Cancer Diagnostics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Cancer Diagnostics Market Definition

Cancer is one of the most popular comprehensive diseases in the world. The process of detecting cancer includes the usage of certain technology and devices specifically used in its diagnosis. Cancer deaths can be prevented and controlled due to proper and prior diagnosis. A cancer diagnosis is defined as the identification of cancer in patients who have developed the signs of the disease. Early diagnosis leads to effective treatment and secures the survival chances of the patient. Effective diagnostic testing is practiced to confirm or exclude the presence of disease, monitor the disease process, and plan for and decide the effectiveness of treatment.

In some cases, it is important to repeat testing when a person's condition has improved, if a sample received was not of good quality, or if an abnormal test result needs to be confirmed. Diagnostic ways for cancer may involve imaging, laboratory tests (including inspections for tumor markers), tumor biopsy, endoscopic examination, surgery, or genetic testing. Cancer diagnosis begins with a physical checkup. The detection of certain biomarkers and proteins that are common in cancer disorders thereby, results in the diagnosis process. Remarkable another process of detecting cancer includes the usage of certain technology and devices particularly used in its diagnosis.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Cancer Diagnostics Market Overview

The global Cancer Diagnostics Market is principally driven by the continual introduction of innovative products, coupled with a growing need for early diagnosis of various diseases. Also, the rapid growth of the healthcare and diagnostics sector can be assigned to the entrance of technologically advanced laboratory systems that have updated oncological screening in producing reliable results. The increasing incidence of cancer is triggering the market for these screening tests and imaging modalities used for observing disease progression, thereby driving the market growth.

According to the World Health Organization (WHO), cancer was the second-leading reason for death globally, subject to approximately 9.6 million deaths in 2018. The National Cancer Insititute (NCI) has determined the number of new cancer cases per year reaches 23.6 million by 2030. Moreover, R&D in cancer diagnostics is also anticipated to aid in the growth of the market. For instance, in January 2020, researchers from Universidade do Porto, Portugal, reported an assessment of the role of O-glycosylation using glycoengineered gastric cancer models in the detection of CD44v9 - a major protein splice variant is forms expressed in human gastrointestinal cancer cells-by monoclonal antibodies.

However, inadequate reimbursement policies are expected to hinder the growth of the market. There have been various advancements in radiology about imaging equipment in the recent past. Most medical insurance companies do not provide reimbursement for procedures utilizing Computer-aided Detection (CAD). Moreover, the high price of cancer detection software is also anticipated to hinder the growth of the market. Computer-aided detection (CAD) software is available with a one-year license and hospitals to have to renew it every year. Nonetheless, the development of biopsy platforms for associate animal cancers is expected to offer profitable growth opportunities for players in the global Cancer Diagnostics Market. Moreover, the use of AI in quick detection of cancer is also supposed to aid in the growth of the market.

Global Cancer Diagnostics Market Segmentation Analysis

The Global Cancer Diagnostics Market is segmented based on Diagnostic Type, Cancer Type, and Geography.

Cancer Diagnostics Market, By Diagnostic Type

• Biopsy and Cytology Tests
• Diagnostic Imaging Tests
• Endoscopy
• Genetic Tests
• Others
• Based on Diagnostic Type, the market is bifurcated into Biopsy and Cytology Tests, Diagnostic Imaging Tests, Endoscopy, Genetic Tests, and Others. The Diagnostic Imaging Tests segment has dominated the major market share and is estimated to witness the highest CAGR for the forecast period. Imaging modalities such as Computed Tomography (CT) scan and Magnetic Resonance Imaging (MRI) are fast, non-invasive, and pain-free diagnostic explications. These imaging modalities are applied as supportive tests along with other laboratory and genetic tests to discover the location and sharpness of the condition in diagnosing a different type of cancer, thereby helping in the choice of a suitable treatment regimen

Cancer Diagnostics Market, By Cancer Type

• Breast Cancer
• Leukemia
• Pancreatic Cancer
• Prostate Cancer
• Colon and Rectal Cancer
• Others

Based on Cancer Type, the market is bifurcated into Breast Cancer, Leukemia, Pancreatic Cancer, Prostate Cancer, Colon and Rectal Cancer, and Others. The Breast Cancer segment is estimated to witness the highest CAGR for the forecast period. The significant causes leading to an upsurge in breast cancer prevalence and percentage rates are hormone replacement therapy, obesity, reduced childbearing and age-related dangers. Transforming lifestyles and increased drink consumption can be directly linked with breast cancer prevalence as well as measure, as it results in an increase in estrogen levels in the body.

Cancer Diagnostics Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world.

Based on Regional Analysis, the Global Cancer Diagnostics Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America dominated the market by capturing the largest revenue share and is expected to continue its lead throughout the forecast period owing to factors such as more prominent funding available for research and development plans and the huge adoption of advanced technologies. The presence of various biotechnology as well as medical device companies in this region is also one of the principal factors driving the diagnostics sector in the region. The Asia Pacific is also expected to grow at a significant rate due to the availability of skilled technicians at a comparatively lower price and a defined regulatory framework favoring advanced product approvals.

Key Players

• The "Global Cancer Diagnostics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Illumina, Inc., Koninklijke Philips N.V., Agilent Technologies, Inc., General Electric Company, F. Hoffmann-La Roche Ltd, and Becton, Dickinson, and Company.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• Product Launches and Merchandise Expansions
• In Nov 2021, Becton, Dickinson, and Co., a key medical devices company, launched a machine-controlled high-throughput diagnostic system for cervical cancer screening, dubbed the Bachelor of Divinity COR PX/GX System.
• In August 2021, the system Approved by the U.S. Food and Drug Administration has been designed to be used in centralized labs and might handle the high-volume process with exaggerated potency.
• Partnerships, Collaborations, and Agreements
• In 2020, GE aid entered a partnership with GenesisCare to boost patient outcomes for the 2 biggest health burdens globally, cancer and cardiovascular disease. GE aid can give CT, MRI, PET/CT, SPECT, digital diagnostic techniques, and ultrasound instrumentation to GenesisCare's 440+ cancer and upset treatment centers across Australia, the US, the UK, and Spain.
• In 2020, Roche medicine entered a partnership with Illumina to supply broad access to clinical medical specialty next-generation sequencing.
• Mergers and Acquisition
• In March 2021, Agilent Technologies INC. nonheritable Resolution natural science, to bolster its headship position in cancer medicine.
• In September 2020, Illumina, Inc.'s nonheritable goblet launched a brand-new section of cancer diagnosing. This acquisition is aimed to accelerate the adoption and commercialization of transformative multi-cancer diagnosing tests with the possibility to observe a lot of cancers earlier and alter higher outcomes.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL CANCER DIAGNOSTICS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL CANCER DIAGNOSTICS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE

• 5.1 Overview
• 5.2 Biopsy and Cytology Tests
• 5.3 Diagnostic Imaging Tests
• 5.4 Endoscopy
• 5.5 Genetic Tests
• 5.6 Others

6 GLOBAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE

• 6.1 Overview
• 6.2 Breast Cancer
• 6.3 Leukemia
• 6.4 Pancreatic Cancer
• 6.5 Prostate Cancer
• 6.6 Colon and Rectal Cancer
• 6.7 Others

7 GLOBAL CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL CANCER DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Illumina, Inc.
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Koninklijke Philips N.V.
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Agilent Technologies, Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 General Electric Company
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 F. Hoffmann-La Roche Ltd.
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Becton, Dickinson and Company
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research